On April 23, 2025 Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "ONO") reported that it will present positive results from the Phase 2 PROSPECT study of tirabrutinib (ONO-4059) for the treatment of relapsed or refractory primary central nervous system lymphoma during an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) being held May 30 to June 3, 2025, in Chicago, Illinois (Press release, Ono, APR 23, 2025, View Source [SID1234652073]). The company will also present data on ONO-4578, an investigational EP4 antagonist, for the treatment of locally advanced resectable rectal cancer, during a poster presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are fully committed to developing innovative drugs for cancer patients. This announcement is an important step forward in demonstrating that we can potentially provide new value to patients," said Tatsuya Okamoto, Corporate Officer / Executive Director, Clinical Development at ONO. "We aim to offer new treatment options in cancer care globally and contribute to improving patients’ quality of life."
Details for both studies and data to be presented are as follows:
Tirabrutinib (ONO-4059)
Abstract Title: Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
Abstract Submission ID: 487376
Session Type and Title: Rapid Oral Abstract – Central Nervous System Tumors
Session Date and Time: May 31, 2025, 3:00-4:30 PM CDT
Presenter: Lakshmi Nayak, MD, Dana-Farber Cancer Institute
ONO-4578
Abstract Title: Neoadjuvant ONO-4578, an EP4 antagonist, in combination with nivolumab after chemoradiation therapy in locally advanced resectable rectal cancer.
Session Type and Title: Poster Session Gastrointestinal Cancer – Colorectal and Anal
Abstract Number for Publication: 3588
Poster Board: 257
Session Date and Time: May 31, 2025, 9:00 AM-12:00 PM CDT
Presenter: Yusuke Takahashi, Lower Gastrointestinal Surgery, National Hospital Organization Osaka National Hospital